Novo Nordisk recently announced plans to invest approximately $100 million to upgrade and expand facilities at its production site in Kalundborg, Denmark.
The facilities are currently manufacturing a range of products for diabetes treatment and will be rebuilt to allow for future production of the next generation of products. The projects are expected to be completed in 2020.
According to Novo Nordisk, these investments are meant to shore up its presence in Denmark and Kalundborg. Novo Nordisk manufactures around half of the world's insulin in Kalundborg, which the company considers a cornerstone of the its global production network.
Novo Nordisk and Novozymes are active partners of the Kalundborg Symbiosis, which is a resource partnership between six private companies and three public operators. The main principle of the industrial symbiosis is that a residue or byproduct from one company becomes a resource in another company's production process. Today, 22 different types of resources are exchanged in the network, resulting in economic and environmental benefits.
Novo Nordisk's production site in Kalundborg also houses production facilities for Novozymes. Established in 1969, the site today covers a total area of 1,200,000 square metres. Novo Nordisk Kalundborg employs close to 3,500 people.
Read the full release.